278 related articles for article (PubMed ID: 29704396)
1. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.
Wozniak A; Scioscia N; García PC; Dale JB; Paillavil BA; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM
Microbiol Immunol; 2018 Jun; 62(6):395-404. PubMed ID: 29704396
[TBL] [Abstract][Full Text] [Related]
2. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
García PC; Paillavil BA; Scioscia N; Dale JB; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM; Wozniak A
Microbiol Immunol; 2018 Nov; 62(11):711-719. PubMed ID: 30357922
[TBL] [Abstract][Full Text] [Related]
3. A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci.
Wozniak A; García P; Geoffroy EA; Aguirre DB; González SA; Sarno VA; Dale JB; Salazar-Echegarai FJ; Vera A; Bueno SM; Kalergis AM
Clin Vaccine Immunol; 2014 Sep; 21(9):1343-9. PubMed ID: 25056362
[TBL] [Abstract][Full Text] [Related]
4. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
5. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
7. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
[TBL] [Abstract][Full Text] [Related]
8. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from
Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF
mBio; 2021 Feb; 12(1):. PubMed ID: 33622722
[TBL] [Abstract][Full Text] [Related]
9. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
Mansour NM; Abdelaziz SA
Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
[TBL] [Abstract][Full Text] [Related]
10. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB
Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757
[TBL] [Abstract][Full Text] [Related]
11. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
Olive C; Clair T; Yarwood P; Good MF
Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of broadly protective group a streptococcal M protein-based vaccines.
Dale JB; Smeesters PR; Courtney HS; Penfound TA; Hohn CM; Smith JC; Baudry JY
Vaccine; 2017 Jan; 35(1):19-26. PubMed ID: 27890396
[TBL] [Abstract][Full Text] [Related]
13. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
14. Similar ability of FbaA with M protein to elicit protective immunity against group A streptococcus challenge in mice.
Ma CQ; Li CH; Wang XR; Zeng RH; Yin XL; Feng HD; Wei L
Cell Mol Immunol; 2009 Feb; 6(1):73-7. PubMed ID: 19254483
[TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
Schulze K; Medina E; Guzmán CA
Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine.
Bruner M; James A; Beall B; Carlone GM; Ades E; Johnson S; Guarner J; Sampson J
Vaccine; 2003 Jun; 21(21-22):2698-703. PubMed ID: 12798606
[TBL] [Abstract][Full Text] [Related]
17. In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci.
Nordström T; Malcolm J; Magor G; Good MF; Batzloff MR
Clin Vaccine Immunol; 2012 Dec; 19(12):1984-7. PubMed ID: 23081813
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
[TBL] [Abstract][Full Text] [Related]
19. Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.
Nordström T; Pandey M; Calcutt A; Powell J; Phillips ZN; Yeung G; Giddam AK; Shi Y; Haselhorst T; von Itzstein M; Batzloff MR; Good MF
J Immunol; 2017 Oct; 199(8):2794-2802. PubMed ID: 28904125
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
McNeil SA; Halperin SA; Langley JM; Smith B; Warren A; Sharratt GP; Baxendale DM; Reddish MA; Hu MC; Stroop SD; Linden J; Fries LF; Vink PE; Dale JB
Clin Infect Dis; 2005 Oct; 41(8):1114-22. PubMed ID: 16163629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
